FTC K-Dur case
Executive Summary
Oral arguments for the Federal Trade Commission's antitrust case against Schering-Plough and Upsher-Smith are scheduled for Jan. 7. FTC is appealing a June 27 decision by an administrative law judge regarding Schering's payments to Upsher so that it would not market a generic version of K-Dur; the judge ruled that such reverse payments are not established antitrust violations (1"The Pink Sheet" July 8, p. 3)...
You may also be interested in...
K-Dur Case: Reverse Payments Not “Established” Antitrust Violations – Judge
Reverse payments from brand to generic companies in patent settlements are not "established" antitrust violations, an administrative law judge said in dismissing the Federal Trade Commission's antitrust case against Schering-Plough regarding K-Dur
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.